Research & Development

Strong energy and constant investment to grow our product portfolio

Big team of professionals with different backgrounds from the life science fields are devoted to the development of affordable products in a vast range of technologies, from injectables to oral solid forms and nasal sprays.

Our R&D operations are based in our R&D center of 300 m2 in Barcelona and a galenical laboratory built in 100m2 in GalenicumSAG facilities in Madrid, Spain.

Our approach to every development is a mixture of applying QbD standards and our knowledge on state of the art technologies, having always in mind the time to market for each of the products.

Once products are commercial, the life cycle management is also paramount and is continuously revised by this team of professionals.

Intellectual Property

One of the most IP active pharma companies in Spain

Galenicum Axium is an IP centric company. We take into account the IP situation and the opportunities derived from our IP research as one of the bases on which we decide to take on projects.

An internal dedicated team performs freedom to operate reports for all our developments and is a key player in the process of designing alternative formulations as well as supporting R&D in the entire development.

Galenicum Axium has already submitted more than 24 patent applications and is actively participating in oppositions with the aim to provide the most secure environment for our customers in the IP landscape.

Clinical affairs

Constant challenge to achieve the most suitable clinical strategies

This experienced team is devoted to design the clinical studies and make the appropriate clinical research needed for the success of our developments.

Our team has the know-how in clinical requirements for different markets worldwide and various types of products. Challenging clinical strategies are always evaluated to assure approvable and affordable products.

We collaborate with GCP compliant CROs, mainly in Europe and Canada. Galenicum Axium has a high success rate in bioequivalence studies, being our goal achieving the 85% success rate.

Regulatory affairs

Consistent relationship and knowledge of Agencies

Galenicum Axium’s regulatory team has extensive knowledge on the EU guidelines, USFDA, ANVISA and beyond, and vast experience in handling different type of procedures, including DCPs and MRPs in the EU market and National Applications in several markets.

This solution driven team has an excellent track record in both initial submissions and variations approved by the Authorities, reaching above 95% approval rates.

The attitude to find solutions as well as the know-how of the product and the Agencies is key to reach this service levels. So we can proudly say that we are a reliable partner in the regulatory space for our customers. 

  • ico_02-20200902120514.svg

    Feasibilities per year

  • imagen-1-20200902074910.png

    success rate goal of bioequivalence studies

  • ico_01-20200902120514.svg

    Prototypes per year

  • bookstack_libr_30241-20200902120514.png

    RA initial submissions approval rate

  • patent-applications1-20200902120514.png

    Number of patent applications

  • check1-20200902120514.png

    RA variation submissions approval rate


Thanks for reaching out. We will get back to you as soon as possible.


The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.

The products mentioned may have a different authorized data sheet in each country.

If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.


DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.